Please login to the form below

Not currently logged in
Email:
Password:

GSK's oncology president joins NuCana board

Paolo Paoletti also has experience in cancer research at Lilly
paolo paoletti NuCana GSK

Dr Paolo Paoletti, the president of oncology at GlaxoSmithKline (GSK), has joined the board of directors at Scottish biotech NuCana BioMed.

Dr Paoletti has been president of oncology as GSK since 2012 having joined the UK-based pharma company in 2005 as head of development in oncology.

During this time he has worked on major cancer products, such as Tykerb/Tyverb and Mekinist.

This experience will benefit Edinburgh-based NuCana as it prepares to advanced development of its pipeline of treatments for advanced solid tumours. This includes Acelarin, which is due to be investigated in 2014 for pancreas, ovarian and biliary cancers.

“We are truly delighted to welcome Paolo to our board,” said Hugh Griffith, NuCana's CEO. “His extensive clinical and commercial experience in oncology will be of enormous benefit to us as we refine our regulatory strategy and expand the clinical development programmes internationally.”

In addition to his ten years at GSK Dr Paoletti's experience in pharma includes a spell at Lilly where his roles included VP of clinical development for the company's oncology business.

2nd December 2014

From: Research

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

Emre Vural
Sourcing R&D innovation: why pharma companies need to evolve their business models
Recent years have seen a significant shift in drug development to specialty areas...
2020 - a year to remember or forget?
2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...
Gilead Headquarters
The search for effective drug treatments for COVID-19
PME talks to Julian Cole, Senior Director, Medical Affairs at Gilead Sciences...

Infographics